Fig. 7: A schematic illustration of anti-tumor effects of iGN.
From: Harnessing an integrated glyco-nanovaccine technology for enhanced cancer immunotherapy
Intradermally injected iGN associates with antigen-presenting cells in tumor-draining lymph nodes to promote antigenic priming of CD8+ T cells. The activated CD8+ T cells infiltrate tumors, leading to destruction of the tumors.
